Abstract
Chong Kun Dang is developing the camptothecin analog CKD-602 for the potential treatment of cancer. By August 2000, phase II trials of CKD-602 were underway.
| Original language | English |
|---|---|
| Pages (from-to) | 1455-1459 |
| Number of pages | 5 |
| Journal | CURRENT OPINION IN INVESTIGATIONAL DRUGS |
| Volume | 4 |
| Issue number | 12 |
| Publication status | Published - 1 Dec 2003 |